Tags: adverse eventsalyconebendamustinebloodblood cancerbortezomibcancercross trial comparisoncyclophosphamidedexamethasoneelderlygerigeriatrichematologyhemeinductionixazomibmaintenancemaintenance therapyMMmultiple myelomaneuropathynewly diagnosed multiple myelomaoncologyorroverall response rateperipheral neuropathypfspnprogression-free survivalsurvivalthalidomidetolerabilitytransplant ineligibletreatment discontinuationvistawell-tolerated
Want more physician-written
medical news?
Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.
Subscribe for free today!